Abstract: Calcitonin is a hormone secreted by the C-cells of the thyroid gland in response to elevations of the plasma calcium level. It reduces bone resorption by inhibiting mature active osteoclasts and increases renal calcium excretion. It is used in the management of postmenopausal osteoporosis, Paget’s disease of bone, and malignancy-associated hypercalcemia. Synthetic and recombinant calcitonin preparations are available; both have similar pharmacokinetic and pharmacodynamic profiles. As calcitonin is a peptide, the traditional method of administration has been parenteral or intranasal. This hinders its clinical use: adherence with therapy is notoriously low, and withdrawal from clinical trials has been problematic. An oral formulation would be more attractive, practical, and convenient to patients. In addition to its effect on active osteoclasts and renal tubules, calcitonin has an analgesic action, possibly mediated through β-endorphins and the central modulation of pain perception. It also exerts a protective action on cartilage and may be useful in the management of osteoarthritis and possibly rheumatoid arthritis. Oral formulations of calcitonin have been developed using different techniques. The most studied involves drug-delivery carriers such as Eligen® 8-(N-2-hydroxy-5-chloro-benzoyl)-amino-caprylic acid (5-CNAC) (Emisphere Technologies, Cedar Knolls, NJ). Several factors affect the bioavailability and efficacy of orally administered calcitonin, including amount of water used to take the tablet, time of day the tablet is taken, and proximity to intake of a meal. Preliminary results looked promising. Unfortunately, in two Phase III studies, oral calcitonin (0.8 mg with 200 mg 5-CNAC, once a day for postmenopausal osteoporosis and twice a day for osteoarthritis) failed to meet key end points, and in December 2011, Novartis Pharma AG announced that it would not pursue further clinical development of oral calcitonin for postmenopausal osteoporosis or osteoarthritis. A unique feature of calcitonin is that it is able to uncouple bone turnover, reducing bone resorption without affecting bone formation and therefore increasing bone mass and improving bone quality. This effect, however, may be dose-dependent, with higher doses inhibiting both resorption and formation. Because so many factors affect the pharmacokinetics and pharmacodynamics of calcitonin, especially orally administered calcitonin, much work remains to be done to explore the full pharmacologic spectrum and potential of calcitonin and determine the optimum dose and timing of administration, as well as water and food intake.

Keywords: oral calcitonin, osteoporosis, fractures, arthritis, pain

Introduction

The purpose of this manuscript is to provide a brief, up-to-date (as of April 2012) review on calcitonin with special emphasis on its clinical efficacy in the management of osteoporosis, arthritis, and pain and on the trials and tribulations of developing an oral formulation.
Methods
We conducted several PubMed Medline literature searches using the following terms: calcitonin, oral calcitonin, pharmacology, pharmacokinetics, pharmacodynamics, bone turnover, osteoporosis, fractures, arthritis, adverse effects, pain, and antibodies. We restricted our search to publications in English and French and focused on clinically relevant publications. We adopted several search categories, including reviews, clinical trials, and meta-analyses. The first search was conducted in October 2011 and the last in April 2012, in order to ensure all recently published data were reviewed. We then classified the retrieved manuscripts into the various categories listed below.

Calcitonin physiology
Calcitonin is a 32-amino acid hormone secreted by the parafollicular (C-cells) of the thyroid gland to regulate calcium homeostasis. The main stimulus to calcitonin secretion is a rise in plasma ionized calcium level.\(^1\) Calcitonin inhibits bone resorption and increases renal calcium loss, thus preventing the plasma calcium level from rising. Excess calcitonin production (as seen in patients with medullary carcinoma of the thyroid) and calcitonin deficiency (as seen in patients with thyroid dysgenesis) affect neither the serum calcium level nor the bone mass, and the administration of calcitonin in therapeutic doses to normal adults does not induce hypocalcemia. Different types of calcitonin have been identified, including human, salmon, eel, and porcine. Salmon calcitonin (sCT) is the most potent,\(^2\) probably because salmon moves rapidly during its migratory course from a low-calcium environment (fresh water) to a calcium-rich environment (sea water).

Calcitonin and bone turnover
Calcitonin directly binds to receptors on the surface of the osteoclasts\(^3\) and induces rapid and reversible changes in their cytoskeleton,\(^4,5\) transiently decreasing their binding to the mineralized bone surface\(^6\) and bone resorptive activity\(^7\) (Figures 1 and 2). Calcitonin specifically targets actively resorbing osteoclasts, and its effect is therefore more pronounced in trabecular than cortical bone, as the turnover rate is higher in the former than the latter. Calcitonin reduces the depth of resorption units, but it does not affect their numbers,\(^8-10\) does not trigger osteoclast apoptosis, and does not reduce the number of osteoclasts.\(^5\) This may have important therapeutic implications, because of the coupling that exists between bone resorption and bone formation and the effect of osteoclasts on osteoblast activity.\(^11\) Calcitonin has the potential to uncouple bone formation from bone

---

Figure 1 Simplified schematic representation of calcitonin, calcium homeostasis, and bone turnover.
resorption, reducing the latter without interfering with the former, provided it is administered in the appropriate dose, as an excessive dose may lead to suppression of both processes. Animal studies have indeed shown that excessive suppression of bone turnover may lead to reduced remodeling, accumulation of microcracks, and increased bone fragility. As 14 of the 32 amino acids of sCT are different from human calcitonin, antibodies against sCT develop in 40% to 70% of patients treated with sCT for more than 4 months. In most instances, however, these antibodies are not neutralizing antibodies, they do not lead to resistance to sCT, and their clinical implications are not fully understood.

The repetitive administration of calcitonin also may diminish its inhibitory activity on osteoclasts, and its long-term administration may lead to the development of osteoclast desensitization and resistance. This is sometimes referred to as the escape phenomenon. Several mechanisms could be responsible, including internalization of calcitonin receptors (CTR) on the surface of the osteoclasts leading to reduced cell surface receptor expression, inhibition of CTR synthesis, inhibition of CTR gene expression, and reduced stability of CTR mRNA. The reduced inhibitory activity appears to be reversible and its clinical implications are not fully understood, as significant improvements in bone mineral density have been reported in patients administered calcitonin daily, intermittently, or cyclically; and daily intranasal sCT administration for 5 years was shown to reduce vertebral fracture risk.

Calcitonin and fracture risk reduction

The fracture risk reduction in patients with osteoporosis treated with calcitonin is modest and much less impressive than that induced by more potent antiresorptive agents. This could explain the findings of the pivotal sCT clinical trial (PROOF study) on postmenopausal women with osteoporosis: At the end of the 5-year study period, sCT induced an increase of only about 1.5% in the bone mineral density (BMD) of the lumbar vertebrae, yet it reduced vertebral fracture risk by 33% to 36%. Changes in biomarkers of bone resorption further support the positive effect of calcitonin on bone “quality”: Whereas bisphosphonates induce significant decreases in the alpha/beta-C telopeptide (C-Tx) ratio (an index of bone age), calcitonin does not. Magnetic resonance imaging (MRI) assessment of trabecular microarchitecture in 91 postmenopausal women who had been administered intranasal sCT or placebo for 2 years showed that, compared to placebo, sCT induced significant improvements (or preservation – ie, no significant loss) in trabecular microarchitecture at multiple skeletal sites.

Calcitonin and bone quality

Calcitonin may improve the “quality” of osteoporotic bone, because the suppression of bone resorption it induces is only transient and not as pronounced as that induced by most other antiresorptive agents. This could explain the findings of the pivotal sCT clinical trial (PROOF study) on postmenopausal women with osteoporosis: At the end of the 5-year study period, sCT induced an increase of only about 1.5% in the bone mineral density (BMD) of the lumbar vertebrae, yet it reduced vertebral fracture risk by 33% to 36%. Changes in biomarkers of bone resorption further support the positive effect of calcitonin on bone “quality”: Whereas bisphosphonates induce significant decreases in the alpha/beta-C telopeptide (C-Tx) ratio (an index of bone age), calcitonin does not. Magnetic resonance imaging (MRI) assessment of trabecular microarchitecture in 91 postmenopausal women who had been administered intranasal sCT or placebo for 2 years showed that, compared to placebo, sCT induced significant improvements (or preservation – ie, no significant loss) in trabecular microarchitecture at multiple skeletal sites.

![Figure 2 Rapid inhibition of osteoclast motility after treatment with salmon calcitonin (sCT) in vitro. Notes: Time-lapse, phase-contrast images courtesy of Tim Arnett (University College London) and David Dempster (Columbia University).](https://www.dovepress.com/)

<table>
<thead>
<tr>
<th>Time</th>
<th>Condition</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>-15 min</td>
<td>50 pg/mL sCT</td>
<td><img src="https://www.dovepress.com/" alt="Image" /></td>
</tr>
<tr>
<td>-5 min</td>
<td></td>
<td><img src="https://www.dovepress.com/" alt="Image" /></td>
</tr>
<tr>
<td>+5 min</td>
<td></td>
<td><img src="https://www.dovepress.com/" alt="Image" /></td>
</tr>
<tr>
<td>+15 min</td>
<td></td>
<td><img src="https://www.dovepress.com/" alt="Image" /></td>
</tr>
</tbody>
</table>

submit your manuscript | www.dovepress.com | Dovepress | 473 | Oral calcitonin

For personal use only. Powered by TCPDF (www.tcpdf.org)
to four different treatment regimens, completed the 5-year study. The conclusion of a meta-analysis of 30 studies was that calcitonin reduces the risk of vertebral fractures and that its effect on nonvertebral fractures is uncertain.

**Routes of administration of calcitonin**

As calcitonin is a polypeptide, the traditional method of administration is parenteral (subcutaneous or intramuscular) or intranasal. It also has been administered rectally. These routes of administration are associated with adverse effects and are inconvenient to many patients. Adherence with calcitonin therapy has been notoriously low, and the high withdrawal rates from clinical trials have been problematic. An oral preparation would be more convenient and acceptable to patients.

Several obstacles affect the bioavailability of orally administered calcitonin. Being a polypeptide, it is readily degraded by gastric acidity and digested by the proteolytic enzymes in the stomach and intestines. Orally administered calcitonin, therefore, must survive first the onslaught of the acidic medium in the stomach and then the gastric and intestinal proteases. Its size and hydrophobicity present further challenges to its intestinal absorption, as it must then cross the epithelial cells lining the intestinal mucosa without interfering with their integrity and without opening the tight junctions of the intestinal mucosa that normally inhibit the passage of large molecules. Only after successfully penetrating the intestinal mucosal cells will calcitonin enter the portal circulation and eventually reach the osteoclasts.

**Oral formulations of calcitonin**

Technological advances made it possible to overcome these obstacles and develop oral formulations of sCT using drug delivery agents or carriers, such as Eligen®-(N-2-hydroxy-5-chloro-benzoyl)-amino-caprylic acid (5-CNAC) (Emisphere Technologies, Cedar Knolls, NJ). These drug delivery agents contain low-molecular weight compounds that combine weakly and noncovalently with sCT to form an insoluble compound at low pH values, thus allowing sCT to cruise through the stomach without being degraded by the acidic medium or the gastric peptidases. Once it reaches the intestines, the compound dissolves in the higher pH environment and, being lipophilic, is absorbed via the passive transcellular pathway, passing through the epithelial cells without undergoing chemical modifications and without compromising the integrity of the intestinal mucosa. Once absorbed, sCT dissociates itself from the delivery agent and reestablishes itself, retaining its biologic state and potential therapeutic activity. This formulation has been tested in Phase 3 studies.

Another successful way of formulating oral calcitonin is by using an acid-resistant enteric coating that prevents dissolution in the stomach and adding citric acid to the tablet core to inhibit intestinal proteases and enhance paracellular transport across the intestinal mucosa. This formulation also has been tested in Phase III studies.

Several other methodologies are available to develop oral formulations of calcitonin, including glycosylation with low-molecular weight polyethylene glycol oligomers to produce small amphiphilic oligomers resistant to proteases and absorbed through the intestinal wall, the addition of protease inhibitors, and encapsulation of sCT in a vehicle containing hydrophilic aromatic alcohols to protect calcitonin from proteases in the stomach and increase its permeability across the intestinal wall.

**Pharmacology of oral calcitonin**

The pharmacokinetics and pharmacodynamics of orally administered calcitonin have been studied in humans. Following the oral administration of 0.8 mg sCT (and 200 mg 5-CNAC), a highly linear dose response and good inverse correlation (r = −0.96) is demonstrated between the area under the curve for sCT (AUC\text{\textsubscript{\text{CT}}}) and for C-telopeptide (AUC\text{\textsubscript{C-Tx}}), an index of bone resorption. Time to maximum concentration is about 15 minutes and half-life is between 9 and 15 minutes, very similar to the pharmacokinetic profile of 200 units intranasally administered sCT. Maximum concentration (C\text{\textsubscript{\text{max}}}), however, is much higher with oral administration than with intranasal: 145 pg/mL and 11.4 pg/mL, respectively, a difference of more than tenfold. Similarly, the AUC\text{\textsubscript{\text{CT}}} and AUC\text{\textsubscript{C-Tx}} are more than tenfold higher with 0.8 mg oral sCT than with 200 units intranasally administered sCT, suggesting that oral sCT is more readily absorbed and inhibits bone resorption to a much greater extent than intranasally administered sCT. This may have significant therapeutic implications, as the greater inhibitory effect of 0.8 mg oral sCT may negate the potential of calcitonin to uncouple bone formation from bone resorption, inhibiting both formation and resorption as opposed to just resorption. Given the differences in C\text{\textsubscript{\text{max}}}, AUC\text{\textsubscript{\text{CT}}} and AUC\text{\textsubscript{C-Tx}} it is possible that a dose of 0.08 mg oral sCT, not 0.8 mg, would have the equivalent biologic effect on bone turnover of 200 units administered intranasally.
Factors affecting pharmacokinetics of orally administered sCT

Several factors affect the bioavailability of orally administered calcitonin, including the following:

Water intake

The amount of water used to take the sCT tablet may affect gastric emptying time and therefore may have a direct impact on sCT bioavailability and bone turnover. This was studied in a randomized, placebo-controlled, single-dose, exploratory crossover Phase I study on 56 healthy postmenopausal women randomly assigned to receive 5 different treatments – 0.8 mg sCT (and 200 mg 5-CNAC) with 50 mL or 200 mL of water, placebo with 50 mL or 200 mL of water, and 200 IU sCT administered intranasally – 10, 30, and 60 minutes before a meal.31 Taking the 0.8 mg sCT tablet (and 200 mg 5-CNAC) with 50 mL of water resulted in two- to threefold increases in AUC \(_{\text{CT}}\) compared to taking the tablet with 200 mL of water and a fourfold increase compared to the intranasally administered sCT; it was also associated with a greater reduction in serum C-Tx levels, indicating a greater reduction in the rate of bone resorption. This effect was independent of whether a meal was consumed 10, 30, or 60 minutes post-dosing, confirming the independent effect of water on the absorption of orally administered sCT. This may have important implications in clinical practice and clinical trials, as the impact on bone turnover may be quite different if a patient takes sCT with 50 or 200 mL of water; whereas a smaller reduction in bone resorption is not likely to affect bone formation, a larger suppression may also decrease bone formation.

Food intake

Food also may affect the bioavailability of orally administered sCT. Compared to dosing 10 minutes before a meal, oral dosing 1, 2, and 4 hours after a meal reduces calcitonin uptake by as much as 74%. This is associated with reduced efficacy as determined by changes in serum C-Tx levels. Taking the tablet 10 minutes before a meal maximizes sCT bioavailability and its effect on bone resorption.31

Time of oral administration

There are marked diurnal and postprandial variations in bone turnover. Bone resorption is about 50% higher in the fasting state than after the intake of a meal and at night during rest than during the day.77 As fasting appears to eliminate most of the circadian variation, it is possible that the observed diurnal variations are secondary to food intake and postprandial endocrine signaling.38,39 To better understand the effect of timing of oral sCT intake on the pharmacokinetic and pharmacodynamic profiles of orally administered sCT, a study was conducted on 81 postmenopausal women.40 They were randomly allocated to receive either placebo or sCT (0.8 mg recombinant sCT and 200 mg 5-CNAC) with 200 mL of water (a) at 8:00 am, after an overnight fast, followed by breakfast 1 hour after dosing (42 subjects, mean age 65.5 years); (b) at 5:00 pm, 4 hours after the previous meal and 1 hour before the next meal (20 subjects, mean age 64.6 years); or (c) at 10:00 pm 4 hours after a meal (19 subjects, mean age 64.4 years). Calcitonin was rapidly absorbed: Median time to \(C_{\text{max}}\) was about 30 minutes for all dosing regimens. \(C_{\text{max}}\) was 45.1, 44.7, and 23.8 pg/mL for the morning, evening, and night doses, respectively. AUC\(_{\text{CT}}\) \(_{0-4\text{ hours}}\) was 30.6, 36.3, and 28.1, respectively. The suppression of bone turnover as determined by reductions in serum C-Tx was 40% to 50% after the morning dose and 75% after the evening and night doses. Given the diurnal and postprandial variations, maximum efficacy was observed after the evening dose, 4 hours after the previous meal and 1 hour before the next meal.40 The correlation between plasma sCT and C-Tx was affected by the time of the day sCT was administered: \(r = -0.96\) when administered in the evening and \(-0.74\) when administered in the morning.35

Tolerability and adverse effects

A 3-month safety and efficacy study on 277 postmenopausal women aged 55 to 85 years showed that oral sCT (combined with 200 mg delivery agent 5-CNAC) was well tolerated, the main adverse effects being mild to moderate gastrointestinal effects in the high-dose group.41 On the other hand, in a 48-week study comparing oral sCT (acid-resistant enteric coated tablets containing citric acid) to intranasal sCT to placebo, about a third of the subjects enrolled withdrew from the study either because of adverse effects – mostly gastrointestinal – or because of withdrawing their consent.32 As patients on placebo in this study also experienced adverse effects, it is possible that these were related to the formulation of the compound or the population included in the study. In another 24-month, Phase III, placebo-controlled clinical trial on the use of oral sCT twice daily (0.8 mg with 5-CNAC carrier delivery system) in 1169 men and women aged 50 to 80 years with painful knee osteoarthritis,42 there were more adverse effects with oral sCT than with placebo, in particular hot flushes (17.8% vs 4.1%), nausea (14% vs 3.1%), dyspepsia (10.1% vs 4.5%) and diarrhea (9.6% vs 4.3%). Discontinuation because of drug-related adverse effects was
19.5% in the sCT group as opposed to 5.8% in the placebo group, and overall discontinuation rate was about 33% in the oral sCT group and 23% in the placebo group. In this study, however, sCT was administered twice daily. All oral formulations do not, therefore, have the same safety/tolerability profile.

Recombinant versus synthetic sCT
Both recombinant and synthetic sCT are available and have similar pharmacodynamic and pharmacokinetic profiles.

Efficacy of oral sCT

Osteoporosis
Several studies have documented the efficacy of oral sCT as determined by changes in biomarkers of bone resorption.

Biomarkers of bone turnover, 3-month study
A 3-month multicenter randomized, double-blind, placebo-controlled, dose-ranging study on 277 postmenopausal women aged 55 to 85 years showed that, compared to placebo, sCT (combined with 200 mg of the delivery agent 5-CNAC) induced dose-dependent decreases in serum C-Tx reaching 81.8% of baseline value 2 to 3 hours post dosing. The formulation was well tolerated.

Bone mineral density and biomarkers of bone turnover, 48-week study (ORACAL trial)
A Phase III multicenter, randomized, double-blind, double-dummy, placebo-controlled study included 565 postmenopausal women (46 to 86 years old) with osteoporosis, as determined by a lumbar vertebrae T-score of −2.5 or lower, or −2.0 and lower if they also had evidence of vertebral fragility fracture. Each patient was randomly allocated to one of three groups: oral recombinant sCT, 0.2 mg taken 1 hour before sleeping; intranasal synthetic sCT, 200 IU; or placebo. All patients also received calcium and vitamin D supplements.

Mean percentage increases in lumbar vertebrae bone mineral density in the oral, intranasal, and placebo groups at 24 weeks were 1.76%, 1.29%, and 0.71% and at 48 weeks were 1.53%, 0.76%, and 0.47%, respectively. Changes in the levels of bone biomarkers (serum C-Tx) at 24 weeks were −42.93%, −24.64%, and −21.09% and at 48 weeks were −29.92%, −11.41%, and −11.83% in the oral, intranasal, and placebo groups, respectively. At 48 weeks, changes in P1NP levels (a marker of bone formation) were −24.17%, −12.44%, and −10.81%, respectively. The greater decrease in P1NP levels at week 48 with the oral formulation than with the intranasal formulation (−24.17% vs −12.44%) may point to different degrees of inhibition of osteoclastic and osteoblastic activity when taken in association with the more pronounced reduction in C-Tx levels (−29.92% oral vs −11.41% intranasal); this suggests that 0.2 mg recombinant sCT may be too high a dose for treating osteoporosis, as it reduces bone formation as well as bone resorption. This observation, however, must be tempered by the large standard deviations of the measured bone biomarkers.

Results of this study are also difficult to interpret because of the relatively small number of patients included (565 randomized to three different study regimens), the short duration of the study (48 weeks), and the overall withdrawal rate (27.3%, 26.5%, and 19.3% in the oral, intranasal and placebo groups, respectively, because of adverse events and withdrawal of consent). Only 176, 128, and 73 participants completed the study in the respective groups.

Fracture risk, 3-year study
A preliminary report of a multicenter, double-blind, placebo-controlled clinical trial on oral sCT (0.8 mg combined with 200 mg of the delivery agent 5-CNAC) in postmenopausal women aged 55 to 85 years with osteoporosis was presented at the 2010 annual meeting of the American Society for Bone and Mineral Research in Chicago. A total of 4,665 postmenopausal women with osteoporosis were enrolled. Their mean age was 66.7 (±6.14) years; mean body mass index 26.1 (±4.16); and baseline T-score < −2.5 in the lumbar vertebrae, femoral neck or total hip. The final analysis was planned for late in 2011. On November 14, 2011, Novartis Pharma AG announced that the study failed to demonstrate a statistically significant reduction in new vertebral fractures at 3 years – the primary end point of the study – and that no significant effect was noted on secondary end points, such as nonvertebral and new clinical fractures. On December 14, 2011, Novartis Pharma AG announced that it would not pursue further clinical development of oral calcitonin as a treatment option for postmenopausal osteoporosis, because oral calcitonin failed to meet key efficacy end points.

Pain
Independent of its activity on bone turnover, calcitonin has an analgesic effect, probably due to increases in plasma β-endorphin levels and interaction with the endogenous opiate system. Calcitonin may also directly modulate pain perception through calcitonin-binding receptors in the median pontine reticular formation and the rostrocaudal
axis of the periaqueductal gray matter. Calcitonin has been shown to be effective at relieving pain in patients with a number of conditions, including acute vertebral compression fractures, bone metastases, Paget’s disease of bone, postoperative pain, diabetic neuropathy, phantom limb pain, adhesive capsulitis, and reflex sympathetic dystrophy.

Osteoarthritis

Increased cartilage degradation is an important aspect of osteoarthritis. Calcitonin receptors have been identified on the surface of articular chondrocytes, and calcitonin has been shown to exert a protective effect on cartilage degradation as measured by changes in C-terminal cross-linked telopeptide of type II collagen, which is present in cartilage.

Cartilage degradation, 2-week study

A 2-week study showed that oral sCT (0.6 mg and 0.8 mg with 200 mg 5-CNAC) administered twice a day led to significant reductions in the rate of cartilage degradation.

Cartilage turnover, 3-month study

A 3-month randomized, double-blind, placebo-controlled study was conducted on 152 women aged 55 to 85 years who were randomly allocated to receive 0.15, 0.4, 1.0, or 2.5 mg oral sCT (each with 200 mg 5-CNAC) or placebo daily. Oral calcitonin induced dose-dependent decreases in 24-hour urinary excretion rates of C-terminal cross-linked telopeptide of type I and II collagen. Greater reductions were noted in patients who had high cartilage turnover rates. Calcitonin therefore may have a role to play in the management of osteoarthritis, especially as it also has an analgesic effect. Calcitonin also enhances the anti-inflammatory effect of corticosteroids and reduces bone and cartilage loss, and therefore may have in addition a role to play in the management of rheumatoid arthritis.

Osteoarthritis of the knee, 24 months

The preliminary results of a 24-month, Phase III clinical trial on the use of oral sCT (0.8 mg twice daily with 5-CNAC carrier delivery system) in 1169 men and women aged 50 to 80 years with painful knee osteoarthritis were presented at the 2011 American College of Rheumatology annual meeting in Chicago. The mean age of the enrolled subjects was 64 years; their mean body mass index was 28.9 kg/m²; and 68% were women. MRI studies demonstrated a 4.5% loss of medial compartment cartilage volume in patients on oral sCT compared to a 7% loss in those on placebo ($P = 0.006$). There were, however, no significant differences in joint-space width in the sCT and placebo groups. Oral sCT was statistically superior to placebo as determined by several scales: 24-hour pain score ($P = 0.018$), patient global assessment ($P = 0.008$), physician global assessment ($P = 0.014$), Western Ontario and McMaster Universities Osteoarthritis Index pain scores ($P = 0.002$), function scores (0.013), and stiffness scores ($P < 0.001$). On December 14, 2011, Novartis Pharma AG announced that it will not pursue further clinical development of oral calcitonin as a treatment option for osteoarthritis because oral calcitonin failed to meet key efficacy endpoints.

Conclusion

Calcitonin is available for the management of postmenopausal osteoporosis, Paget’s disease of bone, and hypercalcemia of malignancy, but its use is limited by the need to administer it parenterally or intranasally and the associated adverse effects. Patient adherence to treatment is notoriously low, and the high withdrawal rate from clinical trials is problematic.

Calcitonin has the potential to uncouple bone resorption from bone formation, inhibiting the former without affecting the latter and thus improving bone quality. The availability of oral formulations should encourage researchers to explore the full pharmacologic spectrum and potential of calcitonin—not limited to osteoporosis, but also including pain relief and possible beneficial effects on osteoarthritis. Preliminary results look encouraging, promising and exciting, but much work remains to be done, especially to identify the optimum dose: too little is not effective, while too much may result in suppression of both bone formation and resorption and may negate the potential unique advantage of calcitonin to uncouple bone formation and resorption. As far as calcitonin is concerned, more is not better.

Given the anticipated long duration of therapy, the oral preparation must be relatively free of adverse effects, including minor gastrointestinal ones. Major challenges include determining the optimum dose and the optimum timing and frequency of oral administration. The full potential of calcitonin has yet to be appreciated.

Acknowledgments

The authors would like to thank Ms Jennifer Culp and Ms Lindy Russell for their assistance in preparing this manuscript.
Disclosures

RCH is on the speakers’ bureau of Novartis. His work as co-author of this manuscript has been performed outside the scope of his employment as a United States government employee. This work represents his personal and professional views and not necessarily those of the US government. DD reports no conflicts of interest in this work.

References


